PharmaMar leads the ONCOLIBERYX consortium together with four research centers for the development of new strategies for the administration of oncological drugs of marine origin

The ONCOLIBERYX project, led by PharmaMar (MSE:PHM), brings together four leading Spanish research groups in nanotechnology and oncology in order to achieve unique formulations that can lead to new oncological therapies based on marine compounds from the PharmaMar collection .

The consortium has the experience and knowledge of renowned Spanish researchers in the field of new drug delivery systems, immunotherapy and cancer, such as Professors Maria Jose Alonso (University of Santiago de Compostela), Maria Blanco Prieto (University of Navarra ), Ignacio Melero (Cima University of Navarra) and Jose Luis Pedraz (University of the Basque Country).

Today, cancer is the second leading cause of death in developed Western countries. Despite notable advances in elucidating the biological mechanisms underlying this disease and new therapeutic approaches, concern about the side effects caused by these drugs is driving the search for more selective and effective therapeutic regimens and formulations.

ONCOLIBERYX focuses on the search for new drug administration strategies in order to increase the specificity of oncological active compounds, reducing their toxicity and side effects, while maintaining and/or increasing their therapeutic effects.

Pilar Calvo, Ph.D. , Responsible for Pharmaceutical Analytics and Development at PharmaMar and technical coordinator of the project, highlights that ' in the last 20 years, drug nanocarriers -liposomes, lipid and polymeric nanoparticles, micelles, antibody-drug conjugates, etc.- have shown notable advantages to meet these challenges. Undoubtedly, the research resulting from PharmaMar's collaboration with these innovative research groups will mean progress in the search for more effective and safe drugs '.

Contact:

Tel: +34 91 846 6000

Fax: 91 846 6001